Related references
Note: Only part of the references are listed.LKB1: Can We Target an Hidden Target? Focus on NSCLC
Gloriana Ndembe et al.
FRONTIERS IN ONCOLOGY (2022)
AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1+ CD8 T cells
Huiyu Li et al.
CELL REPORTS MEDICINE (2022)
Glucocorticoid receptor triggers a reversible drug-tolerant dormancy state with acquired therapeutic vulnerabilities in lung cancer
Stefan Prekovic et al.
NATURE COMMUNICATIONS (2021)
A Real-World Study in Advanced Non-Small Cell Lung Cancer with KRAS Mutations
Lei Lei et al.
TRANSLATIONAL ONCOLOGY (2020)
Functional Versatility of the CDK Inhibitor p57Kip2
Justine Creff et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)
RUVBL1/RUVBL2 ATPase Activity Drives PAQosome Maturation, DNA Replication and Radioresistance in Lung Cancer
Paul Yenerall et al.
CELL CHEMICAL BIOLOGY (2020)
The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non-Small Cell Lung Cancer
Takehito Shukuya et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in KRAS-Mutant Lung Adenocarcinoma
Ana Galan-Cobo et al.
CANCER RESEARCH (2019)
K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways
Matthias Scheffler et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer
Shunsuke Kitapma et al.
CANCER DISCOVERY (2019)
Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer
Elizabeth A. McMillan et al.
CELL (2018)
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma
Ferdinandos Skoulidis et al.
CANCER DISCOVERY (2018)
Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up
H. Kadara et al.
ANNALS OF ONCOLOGY (2017)
A Transcriptional Signature Identifies LKB1 Functional Status as a Novel Determinant of MEK Sensitivity in Lung Adenocarcinoma
Jacob M. Kaufman et al.
CANCER RESEARCH (2017)
LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value
Francesco Facchinetti et al.
LUNG CANCER (2017)
CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells
Jiyeon Kim et al.
NATURE (2017)
Taxane-Platin-Resistant Lung Cancers Co-develop Hypersensitivity to JumonjiC Demethylase Inhibitors
Maithili P. Dalvi et al.
CELL REPORTS (2017)
STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment
Shohei Koyama et al.
CANCER RESEARCH (2016)
LKB1 loss links serine metabolism to DNA methylation and tumorigenesis
Filippos Kottakis et al.
NATURE (2016)
Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma
Erica M. Stringer-Reasor et al.
GYNECOLOGIC ONCOLOGY (2015)
Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities
Ferdinandos Skoulidis et al.
CANCER DISCOVERY (2015)
LKB1 Inactivation Dictates Therapeutic Response of Non-Small Cell Lung Cancer to the Metabolism Drug Phenformin
David B. Shackelford et al.
CANCER CELL (2013)
Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non-Small Cell Lung Cancer
Takeshi Shimamura et al.
CLINICAL CANCER RESEARCH (2013)
Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Esra A. Akbay et al.
CANCER DISCOVERY (2013)
Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
Marcin Imielinski et al.
CELL (2012)
A novel function for Cyclin A2: Control of cell invasion via RhoA signaling
Nikola Arsic et al.
JOURNAL OF CELL BIOLOGY (2012)
Research Resource: Diagnostic and Therapeutic Potential of Nuclear Receptor Expression in Lung Cancer
Yangsik Jeong et al.
MOLECULAR ENDOCRINOLOGY (2012)
p57Kip2 and Cancer: Time for a Critical Appraisal
Adriana Borriello et al.
MOLECULAR CANCER RESEARCH (2011)
Loss of Glucocorticoid Receptor Expression by DNA Methylation Prevents Glucocorticoid Induced Apoptosis in Human Small Cell Lung Cancer Cells
Paul Kay et al.
PLOS ONE (2011)
Simple Combinations of Lineage-Determining Transcription Factors Prime cis-Regulatory Elements Required for Macrophage and B Cell Identities
Sven Heinz et al.
MOLECULAR CELL (2010)
TopHat: discovering splice junctions with RNA-Seq
Cole Trapnell et al.
BIOINFORMATICS (2009)
LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition
C. L. Mahoney et al.
BRITISH JOURNAL OF CANCER (2009)
Somatic LKB1 Mutations Promote Cervical Cancer Progression
Shana N. Wingo et al.
PLOS ONE (2009)
The LKB1-AMPK pathway: metabolism and growth control in tumour suppression
David B. Shackelford et al.
NATURE REVIEWS CANCER (2009)
LKB1 modulates lung cancer differentiation and metastasis
Hongbin Ji et al.
NATURE (2007)
Dexamethasone decreases xenograft response to paclitaxel through inhibition of tumor cell apoptosis
Diana Pang et al.
CANCER BIOLOGY & THERAPY (2006)
Microarray analysis reveals glucocorticoid-regulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells
W Wu et al.
CANCER RESEARCH (2004)
Share Paper
